Ligand Pharmaceuticals. has filed a patent for humanized antibodies with ultralong CDR3 and their various applications. The abstract provides a brief overview of the patent, while the claim has been canceled. GlobalData’s report on Ligand Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ligand Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ligand Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Ligand Pharmaceuticals's grant share as of September 2023 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

Humanized antibodies with ultralong cdr3 and their uses

Source: United States Patent and Trademark Office (USPTO). Credit: Ligand Pharmaceuticals Inc

A recently filed patent (Publication Number: US20230287598A1) describes a bovinized human antibody with specific amino acid substitutions and structural features. The antibody consists of a heavy chain variable domain and a light chain variable domain.

The bovinized human antibody described in claim 20 includes a heavy chain variable domain with specific amino acid substitutions. These substitutions are located at positions 5, 6, 31, 32, and 50 of the amino acid sequence SEQ ID NO: 33. Additionally, the heavy chain variable domain includes an ultralong CDR3 that is at least 35 amino acids long and a framework region 4 (FR4). The light chain variable domain is also present.

Claim 21 specifies that the SEQ ID NO: 33 can have at least two amino acid substitutions selected from Q5R, Q6E, G31D, Y32K, and E50S. Claim 22 extends this to include three, four, or five amino acid substitutions from the same selection.

Claim 23 states that the light chain variable domain can be a VL1-51 light chain variable domain or a variant thereof. Claim 24 further specifies that the light chain variable domain includes the amino acid sequence of SEQ ID NO: 805, with the exception of specific amino acid substitutions at positions corresponding to positions 2, 5, 8, 12, 13, 14, 46, 47, 51, 52, and 53 in SEQ ID NO: 805. These substitutions can include S2A, T5N, P8S, A12G, A13S, P14L, K46R, L47T, D51G, N52D, and N53T.

Claim 26 indicates that the light chain variable region can have at least two of the specified amino acid substitutions. Claim 27 provides options for the amino acid sequence of the FR4 region.

The patent also includes claims related to the antibody's structure and composition. Claim 28 states that the antibody can be a single-chain variable fragment, while claim 29 specifies that the heavy and light chain variable domains can be on different polypeptides.

Overall, this patent describes a bovinized human antibody with specific amino acid substitutions and structural features in its heavy and light chain variable domains. These features may contribute to the antibody's functionality and potential applications in various fields.

To know more about GlobalData’s detailed insights on Ligand Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies